A Randomized, Double-blind, Placebo-controlled, Phase Ib Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Subcutaneous (SC) Doses of HDM1005 Injection in Overweight or Obese Subjects
Latest Information Update: 09 Jul 2025
At a glance
- Drugs HDM 1005 (Primary)
- Indications Obesity
- Focus Adverse reactions
- Sponsors Hangzhou Zhongmei Huadong Pharmaceutical
Most Recent Events
- 01 Jul 2025 Given protocol has been amended as above-1) Status changed from recruiting to completed. 2) Number of treatment arms has been changed from 5 to 4. 3) Actual number of patients has been changed to 40. 4) Sequential assignment has been implemented (parallel assignment has been removed)
- 01 Jul 2025 Status changed from recruiting to completed.
- 22 Oct 2024 New trial record